BCLAF1 and THRAP3 family member 3Genealiases: CXorf23 · TOBF1
Q-omics provides the consensus-scored BCLAF3 profile across patient tissues and cancer cell-line models. BCLAF3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, BCLAF3 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, BCLAF3 RNA expression shows 21,698 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight BRCA, LIHC, and KIRP as cancer lineages where BCLAF3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCLAF3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCLAF3 survival associations across molecular data types. BCLAF3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCLAF3 RNA expression–survival associations across cancer types. High BCLAF3 expression shows unfavorable associations in KICH, LIHC and LGG, but favorable associations in BRCA, SCLC and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for BCLAF3 RNA expression.
This table summarizes BCLAF3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BCLAF3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCLAF3 shows lower tumor expression in LUSC, THCA and UCEC and higher tumor expression in LIHC, CHOL and KIRC. The LIHC box plot shows higher BCLAF3 RNA expression in tumor versus normal tissue (log2 FC = +0.781, t-test p < 0.001).
This table shows molecular features associated with BCLAF3 in patient tissues and cancer cell lines. In patient samples, BCLAF3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, BCLAF3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
